The prescribed dosage for Rezdiffra (resmetirom) may depend on a person’s individual treatment plan. Factors like your medical history and body weight may affect your dosage of Rezdiffra.

The price you pay for Rezdiffra may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biopharmaceutical industry with its flagship product, Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH).

Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges.

By the end of last year, more than 11,800 patients were on Rezdiffra. In a conference call on Wednesday, Madrigal CEO Bill Sibold called the progress “an incredible accomplishment in just nine ...

Rezdiffra reduced liver stiffness by 6.7 kPa at two years, with 51% of patients showing ≥25% improvement in MASH cirrhosis. Madrigal posted a Q4 loss of $2.71 per share, beating estimates, with ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biopharmaceutical industry with its flagship product, Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH). As the ...

On Wednesday, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash ...

Patients on Therapy (End of Q4 2024): Over 11,800 patients actively on Rezdiffra. R&D Expenses (Q4 2024): $25.6 million. R&D Expenses (Full Year 2024): $236.7 million, decreased by $35.6 million ...

The safety and tolerability profile of Rezdiffra in the trial was consistent with previous studies, showing a low rate of discontinuations due to adverse events. Madrigal plans to present ...